Application of electroretinography (ERG) in early drug development for assessing retinal toxicity in rats

Toxicology and Applied Pharmacology

Volumn 289, Issue 3, 2015, Pages 525-533

  Huang, Wenhu ^a   Collette, Walter ^a   Twamley, Michelle ^a   Aguirre, Shirley A ^a   Sacaan, Aida ^a  

^a PFIZER INC   (United States)

Author keywords

Electroretinography; Pan cyclin dependent kinase inhibitors; Rats; Retina; Toxicity

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PARACETAMOL; UNCLASSIFIED DRUG; [4 [[4 AMINO 5 (2,6 DIFLUOROBENZOYL) 1,3 THIAZOL 2 YL]AMINO] N [2 (DIMETHYLAMINO) 1 METHYLETHYL]BENZAMIDE]; [N [[5 [3 (4,6 DIFLUORO 1H BENZO[D]IMIDAZOL 2 YL) 1H INDAZOL 4 YL] 4 METHYLPYRIDIN 3 YL]METHYL)ETHANAMINE]; AG-012986; BENZAMIDE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CYCLIN DEPENDENT KINASE; INDAZOLE DERIVATIVE; N-((5-(3-(4,6-DIFLUORO-1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-5-YL)-4-METHYLPYRIDIN-3-YL)METHYL)ETHANAMINE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B WAVE; CATARACT; CONTROLLED STUDY; DRUG DOSE INCREASE; ELECTRORETINOGRAPHY; EYE TOXICITY; HISTOPATHOLOGY; IN VIVO STUDY; MALE; NONHUMAN; RAT; RETINA DEGENERATION; RETINA INJURY; RETINAL TOXICITY; SENSITIVITY AND SPECIFICITY; TUNEL ASSAY; WEIGHT CHANGE; WEIGHT REDUCTION; WISTAR HANNOVER RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PROCEDURES; RETINA;

ANIMALS; BENZAMIDES; BENZIMIDAZOLES; CYCLIN-DEPENDENT KINASES; DRUG DISCOVERY; ELECTRORETINOGRAPHY; IN SITU NICK-END LABELING; INDAZOLES; INTRAVITREAL INJECTIONS; MALE; RATS; RETINA; RETINAL DEGENERATION; THIAZOLES;

EID: 84947810975     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.10.008     Document Type: Article

References (21)

1. Aguirre S.A., Collette W., Gukasyan H.J., Huang W. An assessment of the ocular safety of excipient maleic acid following intravitreal injection in rabbits. Toxicol. Pathol. 2012, 40:797-806.
2. Aguirre S.A., Huang W., Prasanna G., Jessen B. Corneal neovascularization and ocular irritancy responses in dogs following topical ocular administration of an EP4-prostaglandin E2 agonist. Toxicol. Pathol. 2009, 37:911-920.
3. Casimiro M.C., Velasco-Velazquez M., Aguirre-Alvarado C., Pestell R.G. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert Opin. Investig. Drugs 2014, 23:295-304.
4. Cicenas J., Valius M. The CDK inhibitors in cancer research and therapy. J. Cancer Res. Clin. Oncol. 2011, 137:1409-1418.
5. Cheng Q., Sasaki Y., Shoji M., Sugiyama Y., Tanaka H., Nakayama T., Mizuki N., Nakamura F., Takei K., Goshima Y. Cdk5/p35 and rho-kinase mediate ephrin-A5-induced signaling in retinal ganglion cells. Mol. Cell. Neurosci. 2003, 24:632-645.
6. Huang W., Yang A.H., Matsumoto D., Collette W., Marroquin L., Ko M., Aguirre S., Younis H.S. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J. Ocul. Pharmacol. Ther. 2009, 25:519-530.
7. Illanes O., Anderson S., Niesman M., Zwick L., Jessen B.A. Retinal and peripheral nerve toxicity induced by the administration of a pan-cyclin dependent kinase (cdk) inhibitor in mice. Toxicol. Pathol. 2006, 34:243-248.
8. FDA. http://www.fda.gov/ohrms/dockets/ac/02/slides/3882s1_02_gibertson.pdf.
9. Jonas J.B., Kreissig I., Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative and neovascular diseases. Prog. Retin. Eye Res. 2005, 24:587-611.
10. Krystof V., Uldrijan S. Cyclin-dependent kinase inhibitors as anticancer drugs. Curr. Drug Targets 2010, 11:291-302.
11. Lee M.G., Nurse P. Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 1987, 327:31-35.
12. OECD Test no. 405: acute eye irritation/corrosion, OECD guidelines for the testing of chemicals, section 4 2012, Publishing, OECD. 10.1787/20745788.
13. Pallardy M., Biola A., Lebrec H., Breard J. Assessment of apoptosis in xenobiotic-induced immunotoxicity. Methods 1999, 19:36-47.
14. Peng Q., Huang W., John-Baptiste A. Circulating microRNAs as biomarkers of retinal toxicity. J. Appl. Toxicol. 2014, 34:695-702.
15. Rittenhouse K.D., Johnson T., Vicini P., Hirakawa B., Kalabat D., Yang A.H., Huang W., Basile A.S. RTP801 gene expression is differentially upregulated in retinopathy and is silenced by PF-04523655, a 19-Mer siRNA directed against RTP801. Inest. Ophthalmol. Vis. Sci. 2014, 55:1232-1240.
16. Rosolen S.G., Rigaudière F., Le Gargasson J.F., Brigell M.G. Recommendations for a toxicological screening ERG procedure in laboratory animals. Doc. Ophthalmol. 2005, 110:57-66.
17. Sakamoto K., Ohki K., Sito M., Nakahara T., Ishii K. Small molecule cyclin-dependent kinase inhibitors protect against neuronal cell death in the ischemic-reperfused rat retina. J. Ocul. Pharmacol. Ther. 2011, 27:419-425.
18. Saraste A., Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc. Res. 2000, 45:528-537.
19. Saturno G., Pesenti M., Gavazzoli C., Rossi A., Giusti A.M., Gierke B., Pawlak M., Venturi M. Expression of serine/threonine protein-kinases and related factors in normal monkey and human retinas: the mechanistic understanding of a CDK2 inhibitor induced retinal toxicity. Toxicol. Pathol. 2007, 35:972-983.
20. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 2006, 24:1770-1783.
21. Yang A.H., Huang W. Retinal vein occlusion induced by a MEK inhibitor - impact of oxidative stress on the blood-retinal barrier. Oxidative Stress 2012, 469-494. InTech. V.I. Lushchak, D.V. Gospodaryov (Eds.).